Capstone Therapeutics (NASDAQ:CAPS) Stock Price Down 3.1% – What’s Next?

Posted by Geri Gentry on Jul 12th, 2026

Capstone Therapeutics Corp. (NASDAQ:CAPS – Get Free Report) shares dropped 3.1% on Friday . The company traded as low as $0.25 and last traded at $0.2564. Approximately 124,383 shares traded hands during mid-day trading, a decline of 39% from the average daily volume of 202,915 shares. The stock had previously closed at $0.2647.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Capstone Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, July 2nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Get Our Latest Research Report on Capstone Therapeutics

Capstone Therapeutics Trading Down 3.1%

The stock has a market capitalization of $3.90 million, a price-to-earnings ratio of -0.08 and a beta of -1.51. The company has a debt-to-equity ratio of 0.79, a current ratio of 0.95 and a quick ratio of 0.29. The business’s 50-day simple moving average is $0.31 and its two-hundred day simple moving average is $0.51.

Capstone Therapeutics (NASDAQ:CAPS – Get Free Report) last released its quarterly earnings data on Wednesday, May 20th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). Capstone Therapeutics had a negative return on equity of 114.15% and a negative net margin of 41.26%.The business had revenue of $12.64 million during the quarter, compared to analyst estimates of $10.80 million.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Capstone Therapeutics stock. DRW Securities LLC bought a new position in Capstone Therapeutics Corp. (NASDAQ:CAPS – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned 1.51% of Capstone Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 2.55% of the company’s stock.

Capstone Therapeutics Company Profile

(Get Free Report)

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.